<DOC>
	<DOCNO>NCT00232089</DOCNO>
	<brief_summary>This study do evaluate safety , tolerability satisfactory relief dyspepsia symptom female exclude predominant stomach pain . Tegaserod evaluate 6mg twice daily placebo .</brief_summary>
	<brief_title>Assessment Efficacy Safety Tegaserod Treatment Placebo Women With Dyspepsia</brief_title>
	<detailed_description />
	<mesh_term>Dyspepsia</mesh_term>
	<mesh_term>Tegaserod</mesh_term>
	<criteria>Female patient , 18 year older Selfreported presence persistent recurrent adverse digestive symptom consistent dyspepsia ; least 12 week , necessarily consecutive , previous 12 month . Abnormal esophagogastroduodenoscopy ( EGD ) endoscopy finding esophageal mucosal break , gastric erosion , gastric ulcer and/or duodenal ulcers/erosions EDG exam perform 12 week prior baseline . Current history erosive esophagitis confirm EGD Heartburn occur 3 day week . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Dyspepsia , gastrointestinal , tegaserod</keyword>
</DOC>